Pinnacle Family Advisors LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,582 shares of the company’s stock, valued at approximately $209,000.
Several other hedge funds have also recently bought and sold shares of JNJ. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. BlackRock Inc. raised its stake in shares of Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. State Street Corp raised its stake in shares of Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the last quarter. FMR LLC raised its stake in shares of Johnson & Johnson by 5.9% during the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors raised its stake in shares of Johnson & Johnson by 4.1% during the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after purchasing an additional 1,050,000 shares during the last quarter. 65.89% of the stock is owned by institutional investors and hedge funds.
JNJ has been the subject of several analyst reports. Cowen set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Thursday, August 24th. UBS restated an “underweight” rating on shares of Johnson & Johnson in a research note on Thursday, August 24th. BMO Capital Markets restated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research note on Friday, September 1st. Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research note on Monday, September 18th. Finally, Goldman Sachs Group cut Johnson & Johnson from a “neutral” rating to a “sell” rating and upped their price target for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $145.04.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.68 earnings per share. equities analysts expect that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.36%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.